• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利培酮在人体内的药代动力学:综述。

The pharmacokinetics of risperidone in humans: a summary.

作者信息

Heykants J, Huang M L, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R

机构信息

Department of Drug Metabolism and Pharmacokinetics, Janssen Research Foundation, Beerse, Belgium.

出版信息

J Clin Psychiatry. 1994 May;55 Suppl:13-7.

PMID:7520903
Abstract

Risperidone is rapidly and completely absorbed after oral administration; less than 1% is excreted unchanged in the feces. The principal metabolite was found to be 9-hydroxyrisperidone. Hydroxylation of risperidone is subject to the same genetic polymorphism as debrisoquine and dextromethorphan. In poor metabolizers the half-life of risperidone was about 19 hours compared with about 3 hours in extensive metabolizers. However, becuase the pharmacology of 9-hydroxyrisperidone is very similar to that of risperidone, the half-life for the "active fraction" (risperidone +9-hydroxyrisperidone) was found to be approximately 20 hours in extensive and poor metabolizers. We found that risperidone exhibited linear elimination kinetics and that steady state was reached within 1 day for risperidone and within 5 days for the active fraction.

摘要

利培酮口服后迅速且完全吸收;粪便中以原形排泄的不到1%。主要代谢产物为9-羟利培酮。利培酮的羟基化与异喹胍和右美沙芬存在相同的基因多态性。在代谢缓慢者中,利培酮的半衰期约为19小时,而在代谢快者中约为3小时。然而,由于9-羟利培酮的药理作用与利培酮非常相似,发现“活性部分”(利培酮 + 9-羟利培酮)在代谢快者和代谢缓慢者中的半衰期约为20小时。我们发现利培酮呈现线性消除动力学,利培酮在1天内达到稳态,活性部分在5天内达到稳态。

相似文献

1
The pharmacokinetics of risperidone in humans: a summary.利培酮在人体内的药代动力学:综述。
J Clin Psychiatry. 1994 May;55 Suppl:13-7.
2
Absorption, metabolism, and excretion of risperidone in humans.利培酮在人体内的吸收、代谢及排泄
Drug Metab Dispos. 1993 Nov-Dec;21(6):1134-41.
3
Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.新型抗精神病药物利培酮在健康受试者中的药代动力学及催乳素反应
Clin Pharmacol Ther. 1993 Sep;54(3):257-68. doi: 10.1038/clpt.1993.146.
4
The metabolism and excretion of risperidone after oral administration in rats and dogs.利培酮在大鼠和犬口服给药后的代谢与排泄。
Drug Metab Dispos. 1994 Jan-Feb;22(1):129-38.
5
Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats.大鼠分别口服利培酮和9-羟基利培酮后的脑、血浆及组织药代动力学
Psychopharmacology (Berl). 2002 Feb;159(4):424-31. doi: 10.1007/s00213-001-0933-x. Epub 2001 Nov 20.
6
Pharmacokinetics of risperidone in chronic schizophrenic patients.利培酮在慢性精神分裂症患者中的药代动力学
Psychopharmacol Bull. 1994;30(2):193-7.
7
Pharmacological profile of risperidone.利培酮的药理学特性
Can J Psychiatry. 1993 Sep;38 Suppl 3:S80-8.
8
Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.细胞色素P450 3A抑制剂伊曲康唑影响精神分裂症患者体内利培酮及9-羟基利培酮的血药浓度。
Clin Pharmacol Ther. 2005 Nov;78(5):520-8. doi: 10.1016/j.clpt.2005.07.007. Epub 2005 Sep 26.
9
Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers.两种 2 毫克利培酮口服制剂的相对生物利用度:在健康巴西志愿者中进行的单次、随机、序列、开放标签、两周期交叉比较研究。
Clin Ther. 2010 Nov;32(12):2106-15. doi: 10.1016/j.clinthera.2010.11.006.
10
[Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone].[利培酮及其主要活性代谢物9-羟基利培酮的母体-代谢物药代动力学模型的建立与可识别性分析]
Yao Xue Xue Bao. 2007 Jun;42(6):631-8.

引用本文的文献

1
Population Pharmacokinetics of Risperidone and Paliperidone in Schizophrenia: A Systematic Review.利培酮和帕利哌酮在精神分裂症中的群体药代动力学:一项系统评价。
Pharmaceuticals (Basel). 2025 May 8;18(5):698. doi: 10.3390/ph18050698.
2
Schizophrenia Treatment Based on Sustained Release of Risperidone from Poly(lactic--glycolic) Acid Implantable Microarray Patch.基于从聚乳酸-乙醇酸可植入微阵列贴片持续释放利培酮的精神分裂症治疗
ACS Appl Mater Interfaces. 2025 Mar 19;17(11):16616-16631. doi: 10.1021/acsami.4c20010. Epub 2025 Mar 6.
3
Risperidone plasma level, and its correlation with CYP2D6 gene polymorphism, clinical response and side effects in chronic schizophrenia patients.
利培酮血药浓度及其与 CYP2D6 基因多态性、慢性精神分裂症患者临床疗效及不良反应的相关性
BMC Psychiatry. 2024 Jan 10;24(1):41. doi: 10.1186/s12888-023-05488-z.
4
Racial/Ethnic Differences in the Pharmacokinetics of Antipsychotics: Focusing on East Asians.抗精神病药物药代动力学的种族/民族差异:以东亚人为重点。
J Pers Med. 2022 Aug 24;12(9):1362. doi: 10.3390/jpm12091362.
5
Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone.利培酮在儿童和青少年精神分裂症及其他精神障碍患者中的治疗药物监测。
J Neural Transm (Vienna). 2022 Jun;129(5-6):689-701. doi: 10.1007/s00702-022-02485-6. Epub 2022 Mar 18.
6
Risperidone is not only a prodrug: psychosis induced by medication switch from risperidone to paliperidone - a case report.利培酮不仅是前药:药物转换致精神症状案例报告,由利培酮换用帕利哌酮。
Eur J Hosp Pharm. 2023 Jul;30(4):e20. doi: 10.1136/ejhpharm-2021-002901. Epub 2021 Nov 16.
7
Safety of drug use in patients with a primary mitochondrial disease: An international Delphi-based consensus.原发性线粒体疾病患者药物使用的安全性:基于国际德尔菲共识的研究。
J Inherit Metab Dis. 2020 Jul;43(4):800-818. doi: 10.1002/jimd.12196. Epub 2020 Feb 7.
8
Plasma Risperidone-related Measures in Children and Adolescents with Oppositional Defiant/Conduct Disorders.对立违抗性/品行障碍儿童及青少年的血浆利培酮相关指标
Clin Psychopharmacol Neurosci. 2020 Feb 29;18(1):41-48. doi: 10.9758/cpn.2020.18.1.41.
9
Plasma dopa decarboxylase activity in treatment-resistant recent-onset psychosis patients.难治性近期起病精神病患者的血浆多巴脱羧酶活性
Ther Adv Psychopharmacol. 2019 Sep 6;9:2045125319872341. doi: 10.1177/2045125319872341. eCollection 2019.
10
Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.基于生理学的药代动力学模型描述利培酮及其 9-羟基代谢物在细胞色素 P450 2D6 表型中的药代动力学特征。
Clin Pharmacokinet. 2020 Jan;59(1):51-65. doi: 10.1007/s40262-019-00793-x.